The Technical Analyst
Select Language :

Relay Therapeutics, Inc. [RLAY]
- Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Exchange: NasdaqGM

Last updated: 27 Oct 2021 @ 03:46 am

Relay Therapeutics, Inc. is listed at the NASDAQ Exchange

0.65% $31.14


FUNDAMENTALS
MarketCap: 3 416.12 mill
EPS: -4.81
P/E: 0.000
Earnings Date: Aug 12, 2021
SharesOutstanding: 109.70 mill
Avg Daily Volume: 0.841 mill
RATING 2021-10-25
B
Neutral
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
1/202/203/204/201/212/21
Revenuen/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debt

Insider Trading

Date Person Action Amount type
2021-10-15 Bergstrom Donald A Sell 30 000 Common Stock
2021-09-27 Adams Brian Sell 293 Common Stock
2021-09-27 Catinazzo Thomas Sell 293 Common Stock
2021-09-27 Bergstrom Donald A Sell 646 Common Stock
2021-09-13 Catinazzo Thomas Buy 22 500 Stock Option (Right to Buy)
INSIDER POWER
0.314
Last 93 transactions
Buy: 47 826 721 | Sell: 152 545 100

Forecast: 16:00 - $31.14

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $31.14
Forecast 2: 16:00 - $31.14
Forecast 3: 16:00 - $31.14
SCORE
-2.25
Sell
Score Algorithm Version: 0.9L
Last version updated: Wed 21th July 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $31.14 (0.65% )
Volume 0.317 mill
Avg. Vol. 0.841 mill
% of Avg. Vol 37.65 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Relay Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Relay Therapeutics, Inc.

RSI

Intraday RSI14 chart for Relay Therapeutics, Inc.
The Live Chart for Relay Therapeutics, Inc.
Profile picture for
            Relay Therapeutics, Inc.

RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Last 10 Buy Signals
Date Signal @
BTCUSDOct 26 - 23:1360 612
DOGEUSDOct 26 - 23:08$0.258
XRPUSDOct 26 - 23:051.113
DOGEUSDOct 26 - 22:50$0.258
BTCUSDOct 26 - 22:3060 576
XRPUSDOct 26 - 21:571.116
BTCUSDOct 26 - 21:5460 607
DOGEUSDOct 26 - 21:12$0.258
BTCUSDOct 26 - 21:0760 705
XRPUSDOct 26 - 20:481.112

Stock Peers

Company Price Change
RLAY31.140.65%
ACCD39.41-0.96%
ALXO54.90-0.11%
BNR14.311.92%
FOLD10.35-1.62%
MOR11.772.62%
OPK3.600.00%
ORGO10.90-0.55%
PCRX52.41-0.95%
PTCT35.79-1.13%
RCKT29.32-1.31%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.